Advanced search
Publication Cover
Future Science OA Volume 10, 2024 - Issue 1
Submit an article Journal homepage
174
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel

Priyadharshini Ananthathandavan1 Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science & Technology, Kattankulathur-603203, Chengalpattu, Tamilnadu, IndiaORCID Iconhttps://orcid.org/0000-0002-7936-6093
ORCID Icon &
Damodharan Narayanasamy2 Department of Pharmaceutics, SRM college of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Chengalpattu, Tamilnadu, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4246-5351
ORCID Icon
Article: FSO966 | Received 10 Nov 2023, Accepted 31 Jan 2024, Published online: 20 May 2024

References

  • Jiang XL, Samant S, Lesko LJ et al. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin. Pharmacokinet. 54(2), 147–166 (2015).
  • Polasek TM, Doogue MP, Miners JO. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther. Adv. Drug Saf. 2(6), 253–261 (2011).
  • Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet. Genomics 20(7), 463–465 (2010).
  • Bouziana SD, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J. Gastrointest. Pharmacol. Ther. 6(2), 17–21 (2015).
  • Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann. Intern. Med. 152(6), 337–345 (2010).
  • El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert. Opin. Drug. Metab. Toxicol. 14(4), 447–460 (2018).
  • Mistry SD, Trivedi HR, Parmar DM et al. Impact of proton pump inhibitors on efficacy of clopidogrel: review of evidence. Indian J Pharmacol. 43(2), 183–186 (2011).
  • Roden DM, Shuldiner AR. Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation 22(5), 445–448 (2010).
  • Li Y, Zhang W, Guo D, Zhou G et al. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin. Chim. Acta 391(1–2), 60–67 (2008).
  • Lim IH, Lee SJ, Shin BS et al. Ilaprazole and clopidogrel resistance in acute stroke patients. Biomedicines 10(6), 1366 (2022).
  • Ye Z, Chen P, Tan C, Gong X et al. Effects of ilaprazole on the steady-state pharmacodynamics of clopidogrel in healthy volunteers: an open-label randomized crossover study. Front. Pharmacol. 13, 952804 (2022).
  • Cho H, Choi MK, Cho DY et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J. Clin. Pharmacol. 52(7), 976–984 (2012).
  • Wang H, Shao F, Liu X et al. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. Br. J. Clin. Pharmacol. 85(11), 2547–2558 (2019).
  • Agamah FE, Mazandu GK, Hassan R et al. Computational/in silico methods in drug target and lead prediction. Brief Bioinform. 21(5), 1663–1675 (2020).
  • Dmitriev AV, Filimonov DA, Rudik AV et al. Drug–drug interaction prediction using PASS. SAR QSAR. Environ. Res. 30(9), 655–664 (2019).
  • Dmitriev AV, Rudik AV, Karasev DA et al. In silico prediction of drug–drug interactions mediated by cytochrome P450 isoforms. Pharmaceutics 13(4), 538 (2021).
  • Li Y, Zhang W, Guo D, Zhou G et al. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin. Chim. Acta 391(1–2), 60–67 (2008).
  • Cho H, Choi MK, Cho DY et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J. Clin. Pharmacol. 52(7), 976–984 (2012).
  • Zhang HJ, Zhang XH, Liu J, Sun LN et al. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol. Res. 152, 104606 (2020).
  • Ferreiro JL, Ueno M, Tomasello SD et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ. Cardiovasc. Interv. 4(3), 273–279 (2011).
  • Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7), 713–718 (2009).
  • Valeria C, Carmine S, Valentina M et al. The need of a multicomponent guiding approach to personalize clopidogrel treatment. Pharmacogenomics J. 21(2), 116–127 (2021).
  • Ma TK, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br. J. Clin. Pharmacol. 72(4), 697–706 (2011).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.